lorin bachmann evaluating impact out of control event
Published 2 weeks ago • 74 plays • Length 23:06Download video MP4
Download video MP3
Similar videos
-
1:18
the importance of lymphodepletion, an undervalued component of the car-t therapy cycle
-
2:10
dr arnulf on patient factors and biomarkers that impact pfs with ide-cel in r/r myeloma
-
30:03
irf2 drives interferon-mediated cd8 t cell exhaustion to restrict anti-tumor immunity
-
2:14
how does biomarker testing impact dlbcl treatment options?
-
1:11
distinkt trial analysis: efficacy and safety of imc-001 for r/r enktl
-
3:59
using enhanced ctdna profiling to identify molecular determinants of response in r/r mcl
-
1:13
patient perspectives on rls management
-
2:14
long-term follow-up results from the rathl trial: response-adapted treatment for advanced stage hl
-
1:56
the efficacy of olutasidenib in patients with r/r idh-mutant aml
-
1:38
optimizing biomarker testing to steer treatment decisions
-
1:41
molecular profiling of exceptional responders to cancer therapy
-
1:38
dr. vulfovich on broad molecular profiling in mcrc
-
1:37
a prospective trial of radiation-free chemotherapy in high- and low-risk hl
-
1:28
blood-based biomarkers in huntington’s disease research
-
1:15
dll3, a new biomarker for neuroendocrine tumors of the lung
-
2:47
blood-based biomarkers of pd at the prodromal stage
-
1:24
detection of circulating ttr aggregates: a potential novel biomarker for attr amyloidosis